Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Completed Phase 3 Interventional

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

NCT00232037
View directory record Official record
Conditions
Dyspepsia
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
359 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2008 · Synced Oct 15, 2026, 11:12 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

NCT05929807
View directory record Official record
Conditions
Achondroplasia
Interventions
TransCon CNP
Drug
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Industry
Eligibility
3 Years to 15 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
8
States / cities
Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

NCT00006164
View directory record Official record
Conditions
Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions
Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 11:12 PM EDT
Completed No phase listed Observational

Long-term Follow-up of HALT-C Sustained Virological Responders

NCT00825877
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma, Ascites, Variceal Hemorrhage, Death
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 15, 2026, 11:12 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

NCT01898286
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
DiaPep277®
Drug
Lead sponsor
Andromeda Biotech Ltd.
Industry
Eligibility
18 Years to 47 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Detroit, Michigan • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 15, 2026, 11:12 PM EDT
Completed No phase listed Observational

Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients

NCT01288586
View directory record Official record
Conditions
Primary Arthrosis
Interventions
Scandinavian Total Ankle Replacement System (STAR Ankle)
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Oakland, California • Temple Terrace, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 15, 2026, 11:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Geriatric Anorexia Study 2.0

NCT05211973
View directory record Official record
Conditions
Healthy, Frailty
Interventions
Wrist Actigraphy Device, Smart Body Weight Scale, Chair Scale, Handheld Body Fat Percentage Device, Bioelectric Impedance Analysis Scale
Device
Lead sponsor
Boston University
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 15, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

NCT06199531
View directory record Official record
Conditions
NGLY1 Deficiency
Interventions
GS-100
Genetic
Lead sponsor
Grace Science, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Oakland, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 15, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

NCT05439941
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EDP1815
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 15, 2026, 11:12 PM EDT
Terminated No phase listed Observational

Long-term Health Outcomes of AE Casualties

NCT03736356
View directory record Official record
Conditions
Long Term Adverse Effects, Combat Disorders
Interventions
Not listed
Lead sponsor
Ian Stewart
Federal
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 15, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Nerandomilast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 11:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479
View directory record Official record
Conditions
Severe Asthma
Interventions
Verekitug, Placebo
Drug
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Bakersfield, California • Northridge, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

NCT00658359
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
37
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 15, 2026, 11:12 PM EDT
Completed No phase listed Observational

Long-term LASIK Follow up Study

NCT01695642
View directory record Official record
Conditions
Lasik Eye Surgery
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

NCT04538066
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Colton, California • San Diego, California • Atlantis, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease

NCT02339415
View directory record Official record
Conditions
Inflammation, Coagulation, HIV Infection
Interventions
Edoxaban 30mg daily, Matching placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 15, 2026, 11:12 PM EDT
Recruiting Phase 2 Interventional

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

NCT07550517
View directory record Official record
Conditions
High-Risk Localized Prostate Cancer
Interventions
EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

NCT02057718
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

NCT01175213
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Cypress, California • Irvine, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 15, 2026, 11:12 PM EDT
Completed No phase listed Observational

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

NCT03733496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years and older
Enrollment
14 participants
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 15, 2026, 11:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

NCT05894343
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AAV-GAD
Genetic
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
25 Years to 86 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • West Bloomfield, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Sleep Restriction on Performance in Adults

NCT02960776
View directory record Official record
Conditions
Sleep, Obesity, Sleep Restriction
Interventions
Sleep Restriction (SR)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 15, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03424018
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
6 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 15, 2026, 11:12 PM EDT